Recent Quotes (30 days)

You have no recent quotes
chg | %

DiagnoCure Inc.  

(Public, TSE:CUR)   Watch this stock  
Find more results for CUR
-0.0050 (-33.33%)
May 24 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.01 - 0.01
52 week 0.01 - 0.25
Open 0.01
Vol / Avg. 389,387.00/176,196.00
Mkt cap 645,610.00
P/E     -
Div/yield 0.17/911.50
EPS -0.09
Shares 43.04M
Beta 0.01
Inst. own     -
Jun 10, 2016
Q2 2016 Diagnocure Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 11, 2016
Q1 2016 Diagnocure Inc Earnings Release

Key stats and ratios

Q1 (Jan '16) 2015
Net profit margin -320.64% -698.56%
Operating margin -332.47% -705.57%
EBITD margin - -635.20%
Return on average assets -107.25% -98.34%
Return on average equity - -
Employees 10 -
CDP Score - -


4535 Wilfrid-Hamel Blvd Suite 250
+1-418-5276100 (Phone)
+1-418-5270240 (Fax)

Website links


DiagnoCure, Inc. is a biotechnology company. The Company specializes in the development and commercialization of products relating to the diagnosis of cancer. It intends to focus its activities on business development efforts by out-licensing, selling or partnering with third parties with regards to its Previstage GCC and its new multimarker prostate cancer test (PCP). The Company's colorectal cancer staging test, Previstage GCC, uses the Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. Previstage GCC Colorectal Cancer Staging test is a molecular test for the staging of colorectal cancer patients. The PROGENSA PCA3 assay is a molecular urine test that can be used as a predictor of biopsy outcome in men with a serum prostate specific antigen (PSA) level over 2.5 nanograms per milliliter (ng/ml). Its subsidiaries include Catalyst Oncology LP, 9184-6766 Quebec Inc and 9161-6722 Quebec Inc.

Officers and directors

Yves Fradet M.D. Chairman of the Board, President, Chief Medical Officer
Vincent R. Zurawski Jr., Ph.D. Non Executive Lead Independent Director
Andrew J. Sheldon Independent Director
Jacques Simoneau PH.D. Independent Director
Age: 57
Louise Proulx Ph.D. Non-Executive Independent Director